40112-93-4

Basic information

• Product Name: 4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester
• Synonyms: 4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester;Benzyl 4-(2-Methoxy-2-oxoethylidene)piperidine-1-carboxylate
• CAS NO: 40112-93-4
• Molecular Formula: C₁₆H₁₉NO₄
• Molecular Weight: 289.32636
• Mol File: 40112-93-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester(40112-93-4)
• EPA Substance Registry System: 4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester(40112-93-4)

Safety Data

• Hazardous Substances Data: 40112-93-4(Hazardous Substances Data)

Usage

General Description

4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester, also known as Moclobemide, is a reversible inhibitor of monoamine oxidase A (RIMA). It is used as a medication for the treatment of depression and social anxiety disorder. Moclobemide acts by blocking the breakdown of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain, which can help to improve mood and reduce feelings of anxiety. This chemical compound is a benzyl ester of a carboxylic acid and is classified as a substituted piperidine. Moclobemide has a relatively favorable side effect profile compared to other antidepressant medications, making it a popular choice for individuals who are unable to tolerate the side effects of other antidepressants.

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 1419221-95-6 6-benzyl 1-methyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 
• 30338-85-3 benzyl 4-(2-methoxy-2-oxoethylidene)-3,6-dihydiropyridine-1(2H)-carboxylate 

Relevant articles and documents

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines

Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism.

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.